Physician profile
Badar Muneer
NPI 1609043579
$3,206.30
in general payments reported to CMS, 2019-2025
21 companies · $92.33 in 2025
The $92.33 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,581 · 2020: $368 · 2021: $227 · 2022: $480 · 2023: $327 · 2024: $130 · 2025: $92.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,113.39 | 2019-2020 | |
| Olympus Corporation of The Americas | $769.65 | 2019 | |
| Abbvie INC. | $342.46 | 2019-2025 | |
| Celgene Corporation | $168.34 | 2022-2023 | Zeposia |
| Medtronic, INC. | $162.24 | 2022 | |
| Janssen Biotech, INC. | $104.89 | 2021-2024 | Stelara, Simponi Aria, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $61.95 | 2020-2023 | Entyvio |
| Cumberland Pharmaceuticals, INC. | $54.02 | 2023 | Kristalose |
| Pfizer INC. | $51.39 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $50.71 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $50.05 | 2022-2025 | |
| Novo Nordisk INC | $44.43 | 2025 | Wegovy |
| Evoke Pharma, INC. | $39.57 | 2023 | Gimoti |
| Nestle Healthcare Nutrition INC. | $39.24 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $27.22 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $24.67 | 2022 | |
| Phathom Pharmaceuticals, INC. | $24.08 | 2024 | Voquezna |
| Gilead Sciences, INC. | $23.24 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.75 | 2022 | |
| Aimmune Therapeutics, INC. | $18.71 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Badar Muneer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.